Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX01 vs Rituximab in Low Tumour Burden Follicular Lymphoma
NCT04671420Phase 3Withdrawn
- Sponsor
- Henlius
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Henlius. Primary endpoint: Overall Response Rate at Week 28. Planned start Oct 2020; status: withdrawn.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04671420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671420.